

WEST**Freeform Search****Database:**

US Patents Full-Text Database
 US Pre-Grant Publication Full-Text Database
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Term:

L6 and 12

Display: 10 Documents in Display Format: CIT Starting with Number 1**Generate:** ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search

Clear

Help

Logout

Interrupt

Main Menu

Show S Numbers

Edit S Numbers

Preferences

Cases

Search History**DATE:** Monday, December 01, 2003 [Printable Copy](#) [Create Case](#)Set Name Query
side by sideHit Count Set Name
result set*DB=USPT; PLUR=YES; OP=OR*

<u>L7</u>	L6 and 12	4	<u>L7</u>
<u>L6</u>	L5 and 11	591	<u>L6</u>
<u>L5</u>	L4 and 13	14802	<u>L5</u>
<u>L4</u>	mastocyte degranulation inhibition	102555	<u>L4</u>
<u>L3</u>	IgE and toxin transport	253875	<u>L3</u>
<u>L2</u>	IgE and mastocyte	19	<u>L2</u>
<u>L1</u>	IgE and allergy	2021	<u>L1</u>

END OF SEARCH HISTORY

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 4 of 4 returned.**☐ 1. Document ID: US 6641846 B2

L7: Entry 1 of 4

File: USPT

Nov 4, 2003

US-PAT-NO: 6641846

DOCUMENT-IDENTIFIER: US 6641846 B2

TITLE: Pharmaceutical composition against type I allergy and the preparation thereof

DATE-ISSUED: November 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zhang; Zuoguang	Beijing			CN
Fu; Yanling	Beijing			CN

US-CL-CURRENT: 424/725; 424/439, 424/728, 424/729, 424/739, 424/741, 424/756, 514/2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	---------------------	---------------------------	-----------------------

☐ 2. Document ID: US 6455045 B1

L7: Entry 2 of 4

File: USPT

Sep 24, 2002

US-PAT-NO: 6455045

DOCUMENT-IDENTIFIER: US 6455045 B1

TITLE: Immunogenic compounds with in particular an anti-cytokine effect, preparation process, pharmaceutical compositions and kits containing them

DATE-ISSUED: September 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zagury; Daniel	Paris			FR
Zagury; Jean-Fran.cedilla.ois	Paris			FR
Bizzini; Bernard	Le Mesnil-Saint-Denis			FR

US-CL-CURRENT: 424/184.1; 435/69.1, 530/351

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	---------------------	---------------------------	-----------------------

☐ 3. Document ID: US 6093405 A

L7: Entry 3 of 4

File: USPT

Jul 25, 2000

US-PAT-NO: 6093405

DOCUMENT-IDENTIFIER: US 6093405 A

TITLE: Inactive but immunogenic cytokines, pharmaceutical compositions containing same, and methods of treating homeostatic disorders associated with an overproduction of cytokines

DATE-ISSUED: July 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zagury; Daniel	Paris			FR
Zagury; Jean-Fran.cedilla.ois	Paris			FR
Bizzini; Bernard	Le Mesnil-Saint-Denis			FR

US-CL-CURRENT: 424/198.1; 424/145.1, 424/184.1, 424/85.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KMC	Draw Desc	Image
-----	-----------	-------

☐ 4. Document ID: US 5618842 A

L7: Entry 4 of 4

File: USPT

Apr 8, 1997

US-PAT-NO: 5618842

DOCUMENT-IDENTIFIER: US 5618842 A

TITLE: N-acyl derivatives of aminoalcohols with polycarboxylic acids able to modulate mast cells in inflammatory processes having neuroimmunogenic origin

DATE-ISSUED: April 8, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Della Valle; Francesco	Padua			IT
Lorenzi; Silvana	Padua			IT
Marcolongo; Gabriele	Carrara San Giorgio			IT

US-CL-CURRENT: 514/566; 564/197

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KMC	Draw Desc	Image
-----	-----------	-------

Generate Collection

Print

Terms

Documents

L6 and I2

4

Display Format:

CIT

Change Format

[Previous Page](#)[Next Page](#)

WEST

Generate Collection

Print

L7: Entry 3 of 4

File: USPT

Jul 25, 2000

DOCUMENT-IDENTIFIER: US 6093405 A

TITLE: Inactive but immunogenic cytokines, pharmaceutical compositions containing same, and methods of treating homeostatic disorders associated with an overproduction of cytokines

Brief Summary Text (12):

Other pathological conditions (malignant tumor, allergy, auto-immune illness) can also be the consequence of homeo-static disorders.

Brief Summary Text (54):

This is the case in particular for IL-4 which is a cofactor for stimulation of B-lymphocytes (BL) inducing the production of IgE by said BLs. These IgEs, by their power of degranulation of the basophiles and mastocytes, contribute to pathological manifestations linked to allergy.

Brief Summary Text (57):

The cytokines, fragments or analogues according to the invention can therefore be used according to the cytokine concerned both as a curative and a preventative notably in the treatment of AIDS for IFN-.alpha., in the treatment of allergy for IL-4 and IL-5, in the treatment of certain auto-immune illnesses (lupus erythematosus, rheumatoid polyarthrititis, dermatosclerosis . . .), the treatment of certain cancerous illnesses such as multiple melanoma for IL-6, and more generally the other illnesses brought about by the disruption of an excess of cytokines (including as has been seen the neuropeptides such as somatostatin).

Brief Summary Text (62):

b) A pharmaceutical composition intended for the treatment of a malignant tumor such as a multiple myeloma whose secretion of Ig is linked to IL-6, of an auto-immune illness or of an allergy (urticaria, allergic rhinitis) associated with the hyperproduction of Ig, linked to the over-production of IL-4 or IL-5 which contains, as therapeutic agent, a cytokine, fragment or analogue according to the invention selected from an IL-6, a TGF-.beta., an IL-1, an IL-2, an IFN-gamma, an IL-5 and an IL-4.

Brief Summary Text (69):

(ii) An antigenic determinant characteristic of a pathogenic agent, in a form isolated from said pathogenic agent (sub-unit vaccinal agent); this can be for example a bacterial toxin or a fragment of the latter, a specific antigen of an infectious agent such as a capsular polyside or a fragment of the latter, a viral protein for example an envelope or capsid viral protein or a fragment of the latter and a parasitic antigen or a fragment of the latter, this list being however non-limitative; or

Brief Summary Text (80):

e) The use of a cytokine fragment or analogue according to the invention for therapeutical purposes; in particular, the use of an IL-6, a TGF-.beta., an IL-1, an IL-2, an IFN-gamma, an IL-4 or an IL-5 according to the invention for the treatment of a tumor, an auto-immune infection or an allergy; quite particularly, the use of a TGF-.beta., an IFN-.beta. or an IFN-.alpha. according to the invention for stimulating the immune defences of an individual for example for enhancing the vaccinal power of a conventional vaccinal agent; preferably, the use of an IFN-.alpha. according to the invention for treating a viral infection by an envelope virus, notably HIV.

Brief Summary Text (82):

g) The use of a cytokine, fragment or analogue according to the invention for preparing a pharmaceutical composition intended for the treatment of a malignant tumor and/or of an auto-immune illness and/or of an allergy and/or for the stimulation of the immune defences and/or treatment of an infection by an envelope virus, particularly HIV, notably obtained by the preparation process defined above.

Brief Summary Text (83):

It has also been found that in the case of an infection with an envelope virus, notably a retrovirus, the immuno-suppressive effect could not only be attributed to a hyper-production of cytokines such as IFN-.alpha. in the case of infection with HIV-1 by the infected cells but also to the blocking of the activation of TLs (anergy phenomenon) by peptide elements of the retrovirus itself. These elements act either directly, or by homology with the site of an immunoregulatory substance (mimicry or inhibition) this is the case for the peptide identified by the sequence identifier (hereafter SI) No. 6 below.

CLAIMS:

8. The method in accordance with claim 1, wherein said circulating native cytokine is interleukin-4 (IL-4) or interleukin-5 (IL-5), said pathological condition is an autoimmune disease or an allergy associated with the overproduction of IL-4 or IL-5, and said physically- or chemically-treated, biologically inactivated cytokine is IL-4 or IL-5.

WEST**Freeform Search****Database:**

US Patents Full-Text Database ▲
 US Pre-Grant Publication Full-Text Database
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins ▼

Term:L11 and 110 ▲
▼**Display:** 10 **Documents in Display Format:** CIT **Starting with Number** 1**Generate:** ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search

Clear

Help

Logout

Interrupt

Main Menu

Show S Numbers

Edit S Numbers

Preferences

Cases

Search History**DATE:** Monday, December 01, 2003 [Printable Copy](#) [Create Case](#)**Set Name Query**
side by side**Hit Count Set Name**
result set

DB=USPT; PLUR=YES; OP=OR

<u>L13</u>	L12 and allergic response	796451	<u>L13</u>
<u>L12</u>	L11 and 110	241	<u>L12</u>
<u>L11</u>	fusion protein	187210	<u>L11</u>
<u>L10</u>	L9 and 18	254	<u>L10</u>
<u>L9</u>	inhibition adj mastocyte degranulation	1709	<u>L9</u>
<u>L8</u>	IgE adj toxin transport	252927	<u>L8</u>
<u>L7</u>	L6 and 12	4	<u>L7</u>
<u>L6</u>	L5 and 11	591	<u>L6</u>
<u>L5</u>	L4 and 13	14802	<u>L5</u>
<u>L4</u>	mastocyte degranulation inhibition	102555	<u>L4</u>
<u>L3</u>	IgE and toxin transport	253875	<u>L3</u>
<u>L2</u>	IgE and mastocyte	19	<u>L2</u>
<u>L1</u>	IgE and allergy	2021	<u>L1</u>

END OF SEARCH HISTORY